10 Results

People

  1. Drilon
    Drilon
  2. Hyman
    Hyman
  3. Benayed
    Benayed
  4. Hechtman
    Hechtman
  5. Ladanyi
    Ladanyi
  6. Rosen
    Rosen
  7. Scaltriti
    Scaltriti
  8. Schram
    Schram
  9. Weiss
    Weiss
  10. Bromberg
    Bromberg

Groups

  1. Department of Medicine (10)
  2. Solid Tumor Oncology Division (10)
  3. Thoracic Oncology (10)
  4. Early Drug Development Service (5)
  5. GSK Faculty (3)
  6. MSK Grad Students (3)
  7. Gynecologic Medicine Service (2)
  8. Human Oncology and Pathogenesis Program (2)
  9. Sloan Kettering Institute Postdocs (2)
  10. Tow Center for Developmental Oncology (TCDO) (2)
  1. "adult"
  2. "2020"
  3. "Alexander Drilon"
Formats
  1. Journal Article (10)
Groups
  1. Department of Medicine (10)
  2. Solid Tumor Oncology Division (10)
  3. Thoracic Oncology (10)
  4. Early Drug Development Service (5)
  5. GSK Faculty (3)
  6. MSK Grad Students (3)

More Groups

People
  1. Alexander Drilon (10)
  2. David Hyman (4)
  3. Joshua Weiss (3)
  4. Alison Schram (2)
  5. Ezra Rosen (2)
  6. Jaclyn Hechtman (2)

More People

Years
  1. 2020 (10)
Publications
  1. Lancet Oncology (3)
  2. New England Journal of Medicine (2)
  3. Annals of Oncology (1)
  4. Cancers (1)
  5. Clinical Cancer Research (1)
  6. Journal of Thoracic Oncology (1)

More Publications

Publishers
  1. Elsevier Science, Inc. (3)
  2. Massachusetts Medical Society (2)
  3. American Association for Cancer Research (1)
  4. Elsevier Inc. (1)
  5. MDPI (1)
  6. Nature Publishing Group (1)

More Publishers

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: An intra-patient comparative analysis
    Journal Article

    Italiano, A.; Nanda, S.; Briggs, A.; Garcia-Foncillas, J.; Lassen, U.; Vassal, G.; Kummar, S.; van Tilburg, C. M.; Hong, D. S.; Laetsch, T. W.; more...
    Cancers (2020)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib in RET-altered thyroid cancers
    Journal Article

    Wirth, L. J.; Sherman, E.; Robinson, B.; Solomon, B.; Kang, H.; Lorch, J.; Worden, F.; Brose, M.; Patel, J.; Leboulleux, S.; more...
    New England Journal of Medicine (2020)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer
    Journal Article

    Drilon, A.; Oxnard, G. R.; Tan, D. S. W.; Loong, H. H. F.; Johnson, M.; Gainor, J.; McCoach, C. E.; Gautschi, O.; Besse, B.; Cho, B. C.; more...
    New England Journal of Medicine (2020)

    Fulltext@MSK | Save
  • Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
    Journal Article

    Ross, D. S.; Liu, B.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials
    Journal Article

    Hong, D. S.; DuBois, S. G.; Kummar, S.; Farago, A. F.; Albert, C. M.; Rohrberg, K. S.; van Tilburg, C. M.; Nagasubramanian, R.; Berlin, J. D.; Federman, N.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations
    Journal Article

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies
    Journal Article

    Solomon, B. J.; Tan, L.; Lin, J. J.; Wong, S. Q.; Hollizeck, S.; Ebata, K.; Tuch, B. B.; Yoda, S.; Gainor, J. F.; Sequist, L. V.; more...
    Journal of Thoracic Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1-2 trials
    Journal Article

    Drilon, A.; Siena, S.; Dziadziuszko, R.; Barlesi, F.; Krebs, M. G.; Shaw, A. T.; de Braud, F.; Rolfo, C.; Ahn, M. J.; Wolf, J.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials
    Journal Article

    Doebele, R. C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A. T.; Farago, A. F.; Blakely, C. M.; Seto, T.; Cho, B. C.; Tosi, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
    Journal Article

    Drilon, A.; Clark, J. W.; Weiss, J.; Ou, S. H. I.; Camidge, D. R.; Solomon, B. J.; Otterson, G. A.; Villaruz, L. C.; Riely, G. J.; Heist, R. S.; more...
    Nature Medicine (2020)

    Fulltext@MSK | Save